Novel roles of peroxiredoxins in inflammation, cancer and innate immunity

Journal of Clinical Biochemistry and Nutrition

Volumn 50, Issue 2, 2012, Pages 91-105

  Ishii, Tetsuro ^a   Warabi, Eiji ^a   Yanagawa, Toru ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Cancer; Inflammation; NF B; Peroxiredoxin; Toll like receptor 4

Indexed keywords

ABELSON KINASE; ANDROGEN RECEPTOR; APOPTOSIS SIGNAL REGULATING KINASE 1; CHAPERONE; CISPLATIN; CYCLOPHILIN A; CYTOKINE; GLUTATHIONE TRANSFERASE; HEAT SHOCK PROTEIN; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MACROPHAGE MIGRATION INHIBITION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYC PROTEIN; OZONE; PEROXIREDOXIN; PEROXIREDOXIN 1; PEROXIREDOXIN 2; PEROXIREDOXIN 5; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P66; PROTEIN TYROSINE KINASE; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; BODY FLUID; CANCER CELL; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL DEATH; CHEMOSENSITIVITY; DNA DAMAGE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ERYTHROCYTE; GENE EXPRESSION REGULATION; HELMINTHIASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INNATE IMMUNITY; IONIZING RADIATION; MALARIA; MAMMAL CELL; METASTASIS; NATURAL KILLER CELL; NEOPLASM; NEPHROTOXICITY; NERVE CELL; NONHUMAN; OSTEOARTHRITIS; OXIDATIVE STRESS; PLASMODIUM; PNEUMONIA; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTOZOAL INFECTION; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STRESS; TISSUE REPAIR; TUMOR GROWTH; VIRUS INHIBITION;

MAMMALIA; MUS; PROTOZOA; VERMES;

EID: 84857835586     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.11-109     Document Type: Review

References (173)

1. Yamamoto T, Matsui Y, Natori S, Obinata M. Cloning of a housekeepingtype gene (MER5) preferentially expressed in murine erythroleukemia cells. Gene 1989; 80: 337-343. (Pubitemid 19226586)
2. Chae HZ, Kim IH, Kim K, Rhee SG. Cloning, sequencing, and mutation of thiol-specific antioxidant gene of Saccharomyces cerevisiae. J Biol Chem 1993; 268: 16815-16821. (Pubitemid 23229999)
3. Ishii T, Yamada M, Sato S, et al. Cloning and characterization of a 23-kDa stress-induced mouse peritoneal macrophage protein. J Biol Chem 1993; 268: 18633-18636. (Pubitemid 23273802)
4. Prospéri MT, Ferbus D, Karczinski I, Goubin G. A human cDNA corresponding to a gene overexpressed during cell proliferation encodes a product sharing homology with amoebic and bacterial proteins. J Biol Chem 1993; 268: 11050-11056. (Pubitemid 23162291)
5. Rhee SG, Chae HZ, Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 2005; 38: 1543-1552. (Pubitemid 40726061)
6. Flohé L, Harris JR, eds. Peroxiredoxin Systems. Structure and Functions Subcellular Biochemistry. New York: Springer, Inc., 2007; 44: 1-389.
7. Fujii J, Ikeda Y. Adavances in our understanding of peroxiredoxin, a multifuncational, mammalian redox protein. Redox Rep 2002; 7: 123-130. (Pubitemid 34700435)
8. Ishii T, Yanagawa T. Stress-induced peroxiredoxins. In: Flohe L and Harris JR, eds. Structure and Functions Subcellular Biochemistry. New York: Springer, Inc., 2007; 44: 375-384.
9. 2, a necessary evil for cell signaling. Science 2006; 312: 1882-1883.
10. 2 accumulation for cell signaling. Cell 2010; 140: 517-528.
11. Barranco-Medina S, Lαzaro JJ, Dietz KJ. The oligomeric conformation of peroxiredoxins links redox state to function. FEBS Lett 2009; 583: 1809-1816.
12. Godoy JR, Funke M, Ackermann W, et al. Redox atlas of the mouse: Immunohistochemical detection of glutaredoxin-, peroxiredoxin-, and thioredoxin-family proteins in various tissues of the laboratory mouse. Biochem Biophys Acta 2011; 1810: 2-92.
13. Chang JW, Lee SH, Jeong JY, et al. Peroxiredoxin-I is an autoimmunogenic tumor antigen in non-small cell lung cancer. FEBS Lett 2005; 579: 2873-2877.
14. Furuta T, Imajo-Ohmi S, Fukuda H, Kano S, Miyake K, Watanabe N. Mast cell-mediated immune responses through IgE antibody and Toll-like receptor 4 by malarial peroxiredoxin. Eur J Immunol 2008; 38: 1341-1350.
15. Riddell JR, Wang XY, Minderman H, Gollnick SO. Peroxiredoxin 1 stimulates secretion of proinflammatory cytokines by binding to TLR4. J Immunol 2010; 184: 1022-1030.
16. Shau H, Gupta RK, Golub SH. Identification of a natural killer enhancing factor (NKEF) from human erythroid cells. Cell Immunol 1993; 147: 1-11. (Pubitemid 23100961)
17. Sauri H, Ashjian PH, Kim AT, Shau H. Recombinant natural killer enhancing factor auguments natural killer cytotoxicity. J Leukoc Biol 1996; 59: 925-931. (Pubitemid 26238490)
18. Chang JW, Lee SH, Lu Y, Yoo YJ. Transforming growth factor-β1 induces the non-classical secretion of peroxiredoxin-I in A549 cells. Biochem Biophys Res Commun 2006; 345: 118-123.
19. Jung H, Kim T, Chae HZ, Kim KT, Ha H. Regulation of macrophage migration inhibitory factor and thiol-specific antioxidant protein PAG by direct interaction. J Biol Chem 2001; 276: 15504-15510.
20. Jäschke A, Mi H, Tropschug M. Human T cell cyclophilin 18 binds to thiolspecific antioxidant protein Aop1 and stimulates its activity. J Mol Biol 1998; 277: 763-769. (Pubitemid 28195979)
21. Lee SP, Hwang YS, Kim YJ, et al. Cyclophilin A binds to perosiredoxins and activates its peroxidase activity. J Biol Chem 2001; 276: 29826-29832.
22. Hansen JM, Moriarty-Craige S, Jones DP. Nuclear and cytoplasmic peroxiredoxin-1 differentlly regulate NF-kappaB activities. Free Radic Biol Med 2007; 43: 282-288. (Pubitemid 46977170)
23. Egler RA, Fernandes E, Rothermund K, et al. Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1. Oncogene 2005; 24: 8038-8050. (Pubitemid 41746747)
24. Park SY, Yu X, Ip C, Mohler JL, Bogner PN, Park YM. Peroxiredoxin 1 interacts with androgen receptor and enhances its transactivation. Cancer Res 2007; 67: 9294-9303. (Pubitemid 47535918)
25. Chhipa RR, Lee KS, Onate S, Wu Y, Ip C. Prx1 enhances androgen receptor function in prostate cancer cells by increasing receptor affinity to dihydrotestosterone. Mol Cancer Res 2009; 7: 1543-1552.
26. Kim SY, Kim TJ, Lee KY. A novel function of peroxiredoxin 1 (Prx-1) in apoptosis signal-regulating kinase 1 (ASK1)-mediated signaling pathway. FEBS Lett 2008; 582: 1913-1918.
27. Shc. Aging (Ablany NY) 2009; 1: 254-265.
28. Kim YJ, Lee WS, Ip C, Chae HZ, Park EM, Park YM. Prx1 suppresses radiation-induced c-Jun NH2-terminal kinase signaling in lung cancer cells through interaction with the glutathione S-transferase Pi/c-Jun NH2-terminal kinase complex. Cancer Res 2006; 66: 7136-7142. (Pubitemid 44197691)
29. Hu X, Weng Z, Chu CT, et al. Peroxiredoxin-2 protects against 6-hydroxydopamine- induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade. J Neurosci 2011; 31: 247-261.
30. Ichijo H, Nishida E, Irie K, et al. Induction of apoptosis by ASK1, a mammalian MAP-KKK that activates SAPK/JNK and p38 signaling pathways. Science 1997; 275: 90-94. (Pubitemid 27020316)
31. Saitoh M, Nishitoh H, Fujii M, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 1998; 17: 2596-2606. (Pubitemid 28221195)
32. Adler V, Yin Z, Fuchs SY, et al. Regulation of JNK signaling by GSTp. EMBO J 1999; 18: 1321-1334. (Pubitemid 29110316)
33. Veal EA, Findlay VJ, Day AM, et al. A 2-Cys peroxiredoxin regulates peroxide-induced oxidation and activation of a stress-activated MAP kinase. Mol Cell 2004; 15: 129-139. (Pubitemid 38850225)
34. Fang J, Nakamura T, Cho DH, Gu Z, Lipton SA. S-nitrosylation of perosiredoxin 2 promotes oxidative stress-indiced neuronal cell death in Parkinson's disease. Proc Natl Acad Sci USA 2007; 104: 18742-18747. (Pubitemid 350210767)
35. Qu D, Rashidian J, Mount MP, et al. Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson's disease. Neuron 2007; 55: 37-52. (Pubitemid 46990825)
36. Finetti F, Savino MT, Baldari CT. Positive and negative regulation of antigen receptor signaling by the Shc family of protein adapters. Immuno Rev 2009; 232: 115-134.
37. Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell 2005; 122: 221-233.
38. Shc A at serine 36 in response to ultraviolet irradiation. J Biol Chem 2001; 276: 48332-48336.
39. Shc phosphorylation by ASK1-JNK inactivation in endothelium. Heart Vessels 2007; 22: 423-427.
40. Pinton P, Rimessi A, Marchi S, et al. Protein kinase Cβ and prolyl isomerase regulate mitochondrial effects of the life-span determinant p66Shc. Science 2007; 315: 659-663. (Pubitemid 46214712)
41. Wen ST, Van Etten RA. The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev 1997; 11: 2456-67. (Pubitemid 27438828)
42. Tybulewicz VL, Crawford CE, Jackson PK, Bronson RT, Mulligan RC. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 1991; 65: 1153-1163. (Pubitemid 121001329)
43. Schwartzberg PL, Stall AM, Hardin JD, et al. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell 1991; 65: 1165-1175. (Pubitemid 121001330)
44. Gonfloni S. DNA damage stress response in germ cells: role of c-Abl and clinical implications. Oncogene 2010; 29: 6193-6202.
45. Kharbanda S, Yuan ZM, Weichselbaum R, Kufe D. Determination of cell fate by c-Abl activation in the response to DNA damage. Oncogene 1998; 17: 3309-3318. (Pubitemid 29043983)
46. Ishii T, Itoh K, Takahashi S, et al. Transcription factor Nrf2 coodinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 2000; 275: 16023-16029. (Pubitemid 30366908)
47. Itoh K, Chiba T, Takahashi S, et al. An Nrf2/small maf heterodimer mediates the induction of phase II detoxyfying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997; 236: 313-322. (Pubitemid 27373291)
48. Ishii T, Itoh K, Akasaka J, et al. Induction of murine intestinal and hepatic peroxiredoxin MSP23 by dietary butylated hydroxyanisole. Carcinogenesis 2000; 21: 1013-1016. (Pubitemid 30265148)
49. Shiota M, Izumi H, Miyamoto N, et al. Ets regulates peroxiredoxin1 and 5 expressions through their interaction with the high-mobility group protein B1. Cancer Sci 2008; 99: 1950-1959.
50. Wang MX, Wei A, Yuan J, Trickett A, Knoops B, Murrell GA. Expression and regulation of peroxiredoxin 5 in human osteoarthritis. FEBS Lett 2002; 531: 359-362. (Pubitemid 35341224)
51. Wang MX, Wei A, Yuan J, et al. Antioxidant enzyme peroxiredoxin 5 is upregulated in degenerative human tendon. Biochem Biophys Res Commun 2001; 284: 667-673. (Pubitemid 32924780)
52. Abbas K, Breton J, Picot CR, Quesniaux V, Bouton C, Drapier JC. Signaling events leading to peroxiredoxin 5 up-regulation in immunostimulated macrophages. Free Rad Biol Med 2009; 47: 794-802.
53. Lee KW, Lee DJ, Lee JY, Kang DH, Kwon J, Kang SW. Peroxiredoxin II restrains DNA damage-induced death in cancer cells by positively regulating JNK-dependent DNA repair. J Biol Chem 2011; 286: 8394-8404.
54. Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 1991; 251: 1211-1217. (Pubitemid 21926213)
55. Prendergast GC, Lawe D, Ziff EB. Association of Myn, the murine homolog of max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation. Cell 1991; 65: 395-407. (Pubitemid 121002049)
56. Mu ZM, Yin XY, Prochownik EV. Pag, a putative tumor suppressor, interacts with the Myc Box II domain of c-Myc and selectively alters its biological function and target gene expression. J Biol Chem 2002; 277: 43175-43184. (Pubitemid 35285703)
57. Graves JA, Metukuri M, Scott D, Rothermund K, Prochownik EV. Regulation of reactive oxygen species homeostasis by peroxiredoxins and c-Myc. J Biol Chem 2009; 284: 6520-6529.
58. Kang SW, Chae HZ, Seo MS, Kim K, Baines IC, Rhee SG. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-α. J Biol Chem 1998; 273: 6297-6302. (Pubitemid 28144719)
59. Wang X, He S, Sun JM, Delcuve GP, Davie JR. Selective association of peroxiredoxin 1 with genomic DNA and COX-2 upstream promoter elements in estrogen receptor negative breast cancer cells. Mol Biol Cell 2010; 21: 2987-2995.
60. Zhuang Y, Miskimins WK. Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 2008; 3: 18.
61. Shiota M, Yokomizo A, Kashiwagi E, et al. Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells. Free Rad Biol Med 2011; 51: 78-87.
62. Guo Y, Ma SF, Grigoryev D, Van Eyk J, Barcia JG. 1-DE MS and 2-D LC-MS analysis of the mouse bronchoalveolar lavage proteome. Proteomics 2005; 5: 4608-4624. (Pubitemid 41739938)
63. Gharib SA, Nguyen E, Altemeier WA, et al. Of mice and men: comparative proteomics of bronchoalveolar fluid. Eur Respir J 2010; 35: 1388-1395.
64. 2 level of bone marrow during aging. J Proteome Res 2010; 9: 3812-3819.
65. Catterall JB, Rowan AD, Sarsfield S, Saklatvala J, Wait R, Cawston TE. Development of a novel 2D proteomics approach for the identification of proteins secreted by primary chondrocytes after stimulation by IL-1 and oncostatin M. Rheumatol (Oxford) 2006; 45: 1101-1109. (Pubitemid 44542097)
66. Chang JW, Jeon HB, Lee JH, et al. Augmented expression of peroxiredoxin I in lung cancer. Biochem Biophys Res Commun 2001; 289: 507-512. (Pubitemid 33141083)
67. Massagué J. TGFβ in cancer. Cell 2008; 134: 215-230.
68. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11: 373-384.
69. Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966; 153: 80-82.
70. David JR. Delayed hypertensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 1966; 56: 72-77.
71. Conroy H, Mawhinney L, Donnelly SC. Inflammation and cancer: macrophage migration inhibitory factor (MIF) - the potential missing link. QJM 2010; 103: 831-836.
72. Noels H, Bernhagen J, Weber C. Macrophage migration inhibitory factor: a noncanonical chemokine important in atherosclerosis. Trends Cardiovasc Med 2009; 19: 76-86.
73. Kudrin A, Scott M, Martin S, et al. Human macrophage migration inhibitory factor: a proven immunomodulatory cytokine? J Biol Chem 2006; 281: 29641-29651. (Pubitemid 44536972)
74. Roger T, David J, Glauser MP, Clandra T. MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 2001; 414: 920-924. (Pubitemid 34024744)
75. Takahashi M, Nishihira J, Shimpo M, et al. Macrophage migration inhibitory factor as a redox-sensitive cytokine in cardiac myocytes. Cardiovasc Res 2001; 52: 438-445. (Pubitemid 33153106)
76. Suzuki J, Jin ZG, Meoli DF, Matoba T, Berk BC. Cyclophilin A is secreted by a vesiclar pathway in vascular smooth muscle cells. Circ Res 2006; 98: 811-817.
77. Satoh K, Shimokawa H, Berk BC. Cyclophilin A: promising new target in cardiovascular therapy. Circ J 2010; 74: 2249-2256.
78. Geiben-Lynn R, Kursar M, Brown NV, et al. HIV-1 antiviral activity of recombinant natural killer cell enhancing factors, NKEF-A and NKEF-B, members of the peroxiredoxin family. J Biol Chem 2003; 278: 1569-1574. (Pubitemid 36801385)
79. Watanabe A, Yoneda M, Ikeda F, Sugai A, Sato H, Kai C. Peroxiredoxin 1 is required for the efficient transcription and replication of measles virus. J Virol 2011; 85: 2247-2253.
80. Sawaki J, Tsutsui H, Hayashi N, et al. Type 1 cytokine/chemokine production by mouse NK cells following activation of their TLR/MyD88-mediated pathways. Int Immunol 2007; 19: 311-320. (Pubitemid 46344696)
81. Krockenberger M, Domrowski Y, Weidler C, et al. Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol 2008; 180: 7338-7348.
82. Apte RS, Sinha D, Mayhew E, Wistow GJ, Niederkorn JY. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol 1998; 160: 5693-5696. (Pubitemid 28298023)
83. Arcuri F, Cintorino M, Carducci A, et al. Human decidual natural killer cells as a source and target of macrophage migration inhibitory factor. Reproduction 2006; 131: 175-182. (Pubitemid 43230714)
84. Repp AC, Mayhew ES, Apte S, Niederkorn JY. Human unveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol 2000; 165: 710-715. (Pubitemid 30484736)
85. Müller S. Redox and antioxidant systems of the malaria parasite Plasmodium falciparum. Mol Microbiol 2004; 53: 1291-1305. (Pubitemid 39209105)
86. Deponte M, Rahlfs S, Becker K. Peroxiredoxin systems of protozoal parasites. Subcell Biochem 2007; 44: 219-229.
87. Kehr S, Sturm N, Rahlfs S, Przyborski JM, Becker K. Compartmentation of redox metabolism in malaria parasites. PLoS Pathog 2010; 6: e1001242.
88. Kawazu S, Tsuji N, Hatabu T, Kawai S, Matsumoto Y, Kano S. Molecular cloning and characterization of a peroxiredoxin from the human malaria parasite Plasmodium faciparum. Mol Biochem Parasitol 2000; 109: 165-169. (Pubitemid 30665413)
89. Kawazu S, Komaki K, Tsuji N, et al. Molecular characterization of a 2-Cys peroxiredoxin from the human malaria parasite Plasmodium falciparum. Mol Biochem Parasitol 2001; 116: 73-79. (Pubitemid 32706428)
90. Rahlfs S, Becker K. Thioredoxin peroxidases of the malarial parasite Plasmodium falciparum. Eur J Biochem 2001; 268: 1404-1409. (Pubitemid 32231894)
91. Sarma GN, Nickel C, Rahlfs S, Fischer M, Becker K, Karplus PA. Crystal structure of a novel Plasmodium falciparum 1-Cys peroxiredoxin. J Mol Biol 2005; 346: 1021-1034. (Pubitemid 40215527)
92. Sztajer H, Gamain B, Aumann KD, et al. The putative glutathione peroxidase gene of Plasmodium falciparum codes for a thioredoxin peroxidase. J Biol Chem 2001; 276: 7397-7403.
93. Kawazu S, Komaki-Yasuda K, Oku H, Kano S. Peroxiredoxins in malaria parasites: parasitologic aspects. Parasitol Int 2008; 57: 1-7. (Pubitemid 350116684)
94. Richard D, Bartfai R, Volz J, et al. A genome-wide chromatin-associated nuclear peroxiredoxin from the malaria parasite Plasmodium falciparum. J Biol Chem 2011; 286: 11746-11755.
95. Grau GE, Taylor TE, Molyneux ME, et al. Tumor necrosis factor and disease severity in children with falciparum malaria. New Engl J Med 1989; 320: 1586-1591. (Pubitemid 19154572)
96. Koncarevic S, Rohrbach P, Deponte M, et al. The malarial parasite Plasmodium falciparum imports the human protein peroxiredoxin 2 for peroxide detoxification. Proc Natl Acad Sci USA 2009; 106: 13323-13328.
97. Murphy SC, Samuel BU, Harrison T, et al. Erythrocyte detergent-resistant membrane proteins: their characterization and selective uptake during malarial infection. Blood 2004; 103: 1920-1928. (Pubitemid 38268992)
98. Sam-Yellowe TY. The role of the Maurer's clefts in protein transport in Plasmodium falciparum. Trends Parasitol 2009; 25: 277-284.
99. Henkle-Duhrsekn K, Kampkötter A. Antioxidant enzyme families in parasitic nematodes. Mol Biochem Parasitol 2001; 114: 129-142. (Pubitemid 32510750)
100. Donnelly S, O'Neil SM, Sekiya M, Mulcahy G, Dalton JP. Thioredoxin peroxidase secreted by Fasciola hepatica induces the alternative activation of macrophages. Infect Immun 2005; 73: 166-173. (Pubitemid 40041106)
101. Dzik JM. Molecules released by helminth parasites involved in host colonization. Acta Biochim Pol 2006; 53: 33-64.
102. Robinson MW, Menon R, Donnelly SM, Dalton JP, Ranganathan S. An integrated transcriptomics and proteomics analysis of the secretome of the helminth pathogen Fasciola hepatica: proteins associated with invasion and infection of the mammalian host. Mol Cell Proteomics 2009; 8: 1891-1907.
103. Siracusano A, Riganó R, Ortona E, et al. Immunomodulatory mechanisms during Echinococcus granulosus infection. Exp Parasitol 2008; 119: 483-489.
104. Robinson MW, Hutchison AT, Dalton JP, Donnelly S. Peroxiredoxin: a central player in immune modulation. Parasite Immunol 2010; 32: 305-313.
105. Donnelly S, Stack CM, O'Neil SM, Sayed AA, Williams DL, Dalton JP. Helminth 2-Cys peroxiredoxin drives Th2 responses through a mechanism involving alternatively activated macrophages. FASEB J 2008; 22: 4022-4032.
106. Kinnula VL, Lehtonen S, Kaarteenaho-Wiik R, et al. Cell specific expression of peroxiredoxins in human lung and pulmonary sarcoidosis. Thorax 2002; 57: 157-164. (Pubitemid 34123891)
107. Fisher AB, Dodia C, Feinstein SI, Ho YS. Altered lung phospholipid metabolism in mice with targeted deletion of lysosomal-type phospholipase A2. J Lipid Res 2005; 46: 1248-1256. (Pubitemid 43109839)
108. Wang Y, Feinstein SI, Manevich Y, Ho YS, Fisher AB. Lung injury and mortality with hyperoxia are increased in peroxiredoxin 6 gene-targeted mice. Free Rad Biol Med 2004; 1: 1736-1743. (Pubitemid 39441058)
109. Wang Y, Phelan SA, Manevich Y, Feinstein SI, Fisher AB. Transgenic mice overexpressing peroxiredoxin 6 show increased resistance to lung injury in hyperoxia. Am J Respir Cell Mol Biol 2006; 34: 481-486.
110. Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol 1991; 65: 81-94.
111. Wallach-Dayan SB, Izbicki G, Cohen PY, Gerstl-Golan R, Fine A, Breuer R. Bleomycin initiates apoptosis of lung epithelial cells by ROS but not by Fas/FasL pathway. Am J Physiol Lung Cell Mol Physiol 2006; 290: L790-L796. (Pubitemid 43725085)
112. Kikuchi N, Ishii Y, Morishima Y, et al. Aggravation of bleomycin-induced pulmonary inflammation and fibrosis in mice lacking peroxiredoxin I. Am J Respir Cell Mol Biol 2011; 45: 600-609.
113. Inoue K, Takano H, Koike E, et al. Peroxiredoxin I is a negative regulator of Th2-dominant allergic asthma. Int Immunopharmacol 2009; 9: 1281-1288.
114. Wynalda KM, Murphy RC. Low-concentration ozone reacts with plasmalogen glycerophosphoethanolamine lipids in lung surfactant. Chem Res Toxicol 2010; 23: 108-117.
115. Thompson KC, Rennie AR, King MD, et al. Reaction of a phospholipid monolayer with gas-phase ozone at the air-water interface: measurement of surface excess and surface pressure in real time. Langmuir 2010; 26: 17295-17303.
116. Pulfer MK, Murphy RC. Formation of biologically active oxysterols during ozonolysis of cholesterol present in lung surfactant. J Biol Chem 2004; 279: 26331-26338. (Pubitemid 38798783)
117. Pulfer MK, Taube C, Gelfand E, Murphy RC. Ozone exposure in vivo and formation of biologically active oxysterols in the lung. J Pharmacol Exp Ther 2005; 312: 256-264. (Pubitemid 40096476)
118. Al-Hegelan M, Tighe RM, Castillo C, Hollingsworth JW. Ambient ozone and pulmonary innate immunity. Immunol Res 2011; 49: 173-191.
119. Hollingsworth JW, Kleeberger SR, Foster WM. Ozone and pulmonary innate immunity. Proc Am Thorac Soc 2007; 4: 240-246. (Pubitemid 47036442)
120. Kleeberger SR, Reddy SP, Zhang LY, Cho HY, Jedlicka AE. Toll-like receptor 4 mediates ozone-induced murine lung hyperpermeability via inducible nitric oxide synthase. Am J Physiol Lung Cell Mol Physiol 2001; 280: L326-L333.
121. Hollingsworth JW 2nd, Cook DN, Brass DM, et al. The role of Toll-like receptor 4 in environmental airway injury in mice. Am J Respir Crit Care Med 2004; 170: 126-132. (Pubitemid 38925157)
122. Williams AS, Leung SY, Nath P, et al. Role of TLR2, TLR4 and MyD88 in murine ozone-induced airway hyperresponsiveness and neutrophilia. J Appl Physiol 2007; 103: 1189-1195. (Pubitemid 47610420)
123. Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Toll-like receptor and hyaluronan. Nature Med 2005; 11: 1173-1179. (Pubitemid 43093664)
124. Li Z, Potts EN, Piantadosi CA, Foster WM, Hollingsworth JW. Hyaluronan fragments contribute to the ozone-primed immune response to lipopolysaccharide. J Immunol 2010; 185: 6891-6898.
125. Taylor KR, Yamasaki K, Radek KA, et al. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44 and MD-2. J Biol Chem 2007; 282: 18265-18275. (Pubitemid 47100227)
126. Garantziotis S, Li Z, Potts EN, et al. TLR4 is necessary for hyaluronan-mediated airway hyperresponsiveness after ozone inhalation. Am J Respir Crit Care Med 2010; 181: 666-675.
127. Samet JM, Noah TL, Devlin RB, et al. Effect of ozone on platelet-activating factor production in phorbol-differentiated HL60 cells, a human bronchial epithelial cell line (BEAS S6), and primary human bronchial epithelial cells. Am J Respir Cell Mol Biol 1992; 7: 514-522.
128. Morris GE, Parker LC, Ward JR, et al. Cooperative molecular and cellular networks regulate Toll-like receptor-dependent inflammatory responses. FASEB J 2006; 20: 2153-2155.
129. Ma D, Warabi E, Yanagawa T, et al. Peroxiredoxin I plays a protective role against cisplatin cytotoxicity through mitogen activated kinase signals. Oral Oncol 2009; 45: 1037-1043.
130. Aleksunes LM, Augustine LM, Scheffer GL, Cherrington NJ, Manautou JE. Renal xenobiotic transporters are differently expressed in mice following cisplatin treatment. Toxicology 2008; 250: 82-88.
131. Kang KW, Im YB, Go WJ, Han HK. C-Myc amplification altered the gene expression of ABC- and SLC-transporters in human breast epithelial cells. Mol Pharm 2009; 6: 627-633.
132. Zhang B, Ramesh G, Uematsu S, Akira S, Reeves WB. TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J Am Soc Nephrol 2008; 19: 923-932.
133. Yanagawa T, Iwasa S, Ishii T, et al. Peroxiredoxin I expression in human thyroid tumors. Cancer Lett 1999; 145: 127-132. (Pubitemid 29459080)
134. Yanagawa T, Iwasa S, Ishii T, et al. Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett 2000; 156: 27-35. (Pubitemid 30326764)
135. Yanagawa T, Omura K, Harada H, et al. Peroxiredoxin I expression in tongue squamous cell carcinoma as involved in tumor recurrence. Int J Oral Maxillofac Surg 2005; 34: 915-920. (Pubitemid 41644299)
136. Kim HJ, Chae HZ, Kim YJ, et al. Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biol Toxicol 2003; 19: 285-298. (Pubitemid 38002149)
137. Kinnula VL, Lehtonen S, Sormunen R, et al. Overexpression of peroxiredoxins I, II, III, V and VI in malignant mesothelioma. J Pathol 2002; 196: 316-323. (Pubitemid 34189421)
138. Riddell JR, Bshara W, Moser MT, Spernyak JA, Foster BA, Gollnick SO. Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4- dependent regulation of tumor vasculature. Cancer Res 2011; 71: 1-10.
139. He W, Liu Q, Wang L, Chen W, Li N, Cao X. TLR4 signaling promotes immune escape of human cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 2007; 44: 2850-2859. (Pubitemid 46412506)
140. Szczepanski MJ, Czystowska M, Szajnik M, et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 2009; 69: 3105-3113.
141. Szajnik M, Szczepanski MJ, Czystowska M, et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene 2009; 28: 4353-4363.
142. Lokeshwar VB, Selzer MG. Hyaluronidase: both a tumor promoter and suppressor. Semin Cancer Biol 2008; 18: 281-287.
143. Girish KS, Kemparaju K. The magic glue hyaluronan and its eraser hyaluronidase: a biological overview. Life Sci 2007; 80: 1921-1943. (Pubitemid 46601516)
144. Wei Q, Jiang H, Xiao Z, et al. Sulfiredoxin-Peroxiredoxin IV axia promotes human lung cancer progression through modulation of specific phosphokinase signaling. Proc Natl Acad Sci USA 2011; 108: 7004-7009.
145. Giguère P, Turcotte ME, Hamelin E, et al. Peroxiredoxin-4 interacts with and regulates the thromboxane A2 receptor. FEBS Lett 2007; 581: 3863-3868. (Pubitemid 47102313)
146. Chang XZ, Li DQ, Hou YF, et al. Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res 2007; 9: R76.
147. Lehtonen ST, Svensk AM, Soini Y, et al. Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer 2004; 111: 514-521. (Pubitemid 39045317)
148. Karihtala P, Mäntyniemi A, Kang SW, Kinnula VL, Soini Y. Peroxiredoxins in breast carcinoma. Clin Cancer Res 2003; 9: 3418-3424. (Pubitemid 37082738)
149. Li DQ, Wang L, Fei F, et al. Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using twodimesional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics 2006; 6: 3352-3368. (Pubitemid 43886152)
150. Manevich Y, Fisher AB. Peroxiredoxin 6, a 1-Cys peroxiredoxin, functions in antioxidant defense and lung phospholipid metabolism. Free Radic Biol Med 2005; 38: 1422-1432. (Pubitemid 40693827)
151. 2 activities. Biochimie 2010; 92: 638-644.
152. Liu G, Feinstein SI, Wang Y, et al. Comparison of glutathione peroxidase 1 and peroxiredoxin 6 in protection against oxidative stress in the mouse lung. Free Radic Bio Med 2010; 49: 1172-1181.
153. Ho JN, Lee SB, Lee SS, et al. Phospholipase A2 activity of peroxiredoxin 6 promotes invasion and metastasis of lung cancer cells. Mol Cancer Ther 2010; 9: 825-832.
154. 2 activation and lipid generation in lipopolysaccharide-stimulated macrophages. J Biol Chem 2005; 280: 38969-38975.
155. Ruipèrez V, Astudillo AM, Balboa MA, Balsinde J. Coordinate regulation of TLR-mediated arachidonic acid mobilization in macrophages by group IVA and group V phospholipase A2s. J Immunol 2009; 182: 3877-3883.
156. 2)alpha/cyclooxygenase-2. J Cell Physiol 2010; 223: 480-491.
157. Wu Y, Feinstein SI, Manevich Y, et al. Mitogen-activated protein kinase-mediated phosphorylation of peroxiredoxin 6 regulates its phospholipase A2 activity. Biochem J 2009; 19: 669-679.
158. Neumann CA, Krause DS, Carman CV, et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 2003; 424: 561-565. (Pubitemid 36975778)
159. Cao J, Schulte J, Knight A, et al. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J 2009; 28: 1505-1517.
160. Zhang S, Yu D. PI(3)king apart PTEN's role in cancer. Clin Cancer Res 2010; 16: 4325-4330.
161. Huo YY, Li G, Duan RF, et al. PTEN deletion leads to deregulation of antioxidants and increased oxidative damage in mouse embryonic fibroblasts. Free Radic Biol Med 2008; 44: 1578-1591.
162. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The PI 3-kinase/ Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kB and c-Myc in pancreatic cancer cells. Oncogene 2004; 23: 8571-8580. (Pubitemid 39576463)
163. Kim J, Eltoum IE, Roh M, Wang J, Abdulkadir SA. Interactions between cells with distinct mutations in c-Myc and Pten in prostate cancer. PLoS Genet 2009; 5: e1000542.
164. Uwayama J, Hirayama A, Yanagawa T, et al. Tissue Prx I in the protection against Fe-NTA and the reduction of nitroxyl radicals. Biochem Biophys Res Commun 2006; 339: 226-231. (Pubitemid 41697539)
165. Hotez PJ, Narasimhan S, Haggerty J, et al. Hyaluronidase from infective Ancylostoma hookworm larvae and its possible function as a virulence factor in tissue invasion and in cutaneous larva migrans. Infect Immun 1992; 60: 1018-1023.
166. Sironen RK, Tammi M, Tammi R, Auvinen PK, Anttila M, Kosma VM. Hyaluronan in human malignancies. Exp Cell Res 2011; 317: 383-391.
167. Itano N, Zhuo L, Kimata K. Impact of the hyaluronan-rich tumor microenvironment on cancer initiation and progression. Cancer Sci 2008; 99: 1720-1725.
168. Joly AL, Wettstein G, Mignot G, Ghringhelli F, Garrido C. Dual role of heat shock proteins as regulators of apoptosis and innate immunity. J Innate Immun 2010; 2: 238-247.
169. Pockley AG, Muthana M, Calderwood SK. The dual immunoregulatory roles of stress proteins. Trends Biochem Sci 2008; 33: 71-79.
170. Calderwood SK, Mambula SS, Gray PJ Jr., Theriault JR. Extracellular heat shock proteins in cell signaling. FEBS Lett 2007; 581: 3689-3694. (Pubitemid 47081004)
171. Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol 2007; 81: 15-27. (Pubitemid 46021247)
172. Molvarec A, Tamasi L, Losonczy G, Madách K, Prohászka Z, Rigó J Jr. Circulating heat shock protein 70 (HSPA1A) in normal and pathological pregnancies. Cell Stress Chaperones 2010; 15: 237-247.
173. Nakamura H, Masutani H, Yodoi J. Extracellular thioredoxin and thoredoxin-binding protein 2 in control of cancer. Semin Cancer Biol 2006; 16: 444-451. (Pubitemid 44780134)